Insider Trading Alert - ARCB, RFMD And INSY Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, May 15, 2014, 142 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $600.00 to $30,330,507.50.

Highlighted Stocks Traded by Insiders:

ArcBest (ARCB) - FREE Research Report

Johns Michael R, who is VP - Gen Counsel & Corp Sec at ArcBest, sold 4,700 shares at $41.57 on May 15, 2014. Following this transaction, the VP - Gen Counsel & Corp Sec owned 33,703 shares meaning that the stake was reduced by 12.24% with the 4,700-share transaction.

The shares most recently traded at $39.83, down $1.74, or 4.36% since the insider transaction. Historical insider transactions for ArcBest go as follows:

  • 4-Week # shares sold: 9,606
  • 12-Week # shares sold: 9,606
  • 24-Week # shares sold: 12,230

The average volume for ArcBest has been 330,300 shares per day over the past 30 days. ArcBest has a market cap of $1.1 billion and is part of the services sector and transportation industry. Shares are up 19.48% year-to-date as of the close of trading on Thursday.

ArcBest Corporation provides freight transportation services and integrated logistics solutions worldwide. The stock currently has a dividend yield of 0.29%. The company has a P/E ratio of 45.1. Currently, there are 2 analysts who rate ArcBest a buy, no analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ARCB - FREE

TheStreet Quant Ratings rates ArcBest as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and good cash flow from operations. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full ArcBest Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

RF Micro Devices (RFMD) - FREE Research Report

Gardner Jeffery R, who is Director at RF Micro Devices, sold 15,000 shares at $8.82 on May 15, 2014. Following this transaction, the Director owned 107,450 shares meaning that the stake was reduced by 12.25% with the 15,000-share transaction.

The shares most recently traded at $8.66, down $0.16, or 1.85% since the insider transaction. Historical insider transactions for RF Micro Devices go as follows:

  • 4-Week # shares sold: 289,216
  • 12-Week # shares sold: 373,245
  • 24-Week # shares sold: 527,465

The average volume for RF Micro Devices has been 11.8 million shares per day over the past 30 days. RF Micro Devices has a market cap of $2.5 billion and is part of the technology sector and electronics industry. Shares are up 69.28% year-to-date as of the close of trading on Thursday.

RF Micro Devices, Inc. engages in the design, development, manufacture, and marketing of radio frequency (RF) solutions for original equipment manufacturers and original design manufacturers in wireless and wired communications applications in the United States and internationally. The company has a P/E ratio of 218.5. Currently, there are 8 analysts who rate RF Micro Devices a buy, 1 analyst rates it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on RFMD - FREE

TheStreet Quant Ratings rates RF Micro Devices as a hold. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we find that the company's revenue growth has not been good. Get the full RF Micro Devices Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Insys Therapeutics (INSY) - FREE Research Report

Meyer Steven J, who is Director at Insys Therapeutics, bought 5,000 shares at $21.38 on May 15, 2014. Following this transaction, the Director owned 5,000 shares meaning that the stake was reduced by 100% with the 5,000-share transaction.

Fourteau Patrick, who is Director at Insys Therapeutics, bought 7,500 shares at $22.77 on May 15, 2014. Following this transaction, the Director owned 105,000 shares meaning that the stake was reduced by 7.69% with the 7,500-share transaction.

The shares most recently traded at $23.86, up $1.09, or 4.57% since the insider transaction. Historical insider transactions for Insys Therapeutics go as follows:

  • 4-Week # shares bought: 500
  • 4-Week # shares sold: 1,262
  • 12-Week # shares bought: 500
  • 12-Week # shares sold: 1,262
  • 24-Week # shares bought: 1,000
  • 24-Week # shares sold: 1,262

The average volume for Insys Therapeutics has been 592,700 shares per day over the past 30 days. Insys Therapeutics has a market cap of $786.8 million and is part of the health care sector and drugs industry. Shares are down 12.43% year-to-date as of the close of trading on Thursday.

Insys Therapeutics, Inc., a commercial-stage specialty pharmaceutical company, develops and commercializes supportive care products. It focuses on utilizing its proprietary formulation technologies to address the clinical shortcomings of existing commercial pharmaceutical products. The company has a P/E ratio of 14.3. Currently, there are 2 analysts who rate Insys Therapeutics a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on INSY - FREE

TheStreet Quant Ratings rates Insys Therapeutics as a hold. The company's strengths can be seen in multiple areas, such as its notable return on equity, robust revenue growth and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we find that the growth in the company's earnings per share has not been good. Get the full Insys Therapeutics Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
null

If you liked this article you might like

This Portfolio of 10 Profitable Small-Caps Has Produced Profitable Returns

This Portfolio of 10 Profitable Small-Caps Has Produced Profitable Returns

The Small Caps With Cash Portfolio Powers Ahead

The Small Caps With Cash Portfolio Powers Ahead

My Small-Cap Value Portfolio Is Proving Its Value

My Small-Cap Value Portfolio Is Proving Its Value

Ex-Dividend Alert: 3 Stocks Going Ex-Dividend Tomorrow: CIK, CHY, ARCB

Ex-Dividend Alert: 3 Stocks Going Ex-Dividend Tomorrow: CIK, CHY, ARCB

ArcBest (ARCB) Stock: Weak On High Volume Today

ArcBest (ARCB) Stock: Weak On High Volume Today